Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CTIC
- Price
- -
- Stock movement up
- +- (%)
- Company name
- CTi Biopharma Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.20B
- Ent value
- 1.31B
- Price/Sales
- 15.82
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 101.00
- PEG
- -
- EPS growth
- -6.19%
- 1 year return
- 52.52%
- 3 year return
- 93.74%
- 5 year return
- 13.15%
- 10 year return
- -3.29%
Last updated: 2024-12-17
DIVIDENDS
CTIC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.82 |
| Price to Book | - |
| EV to Sales | 17.32 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 131.88M |
| EPS (TTM) | -0.59 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 75.77M |
| Gross profit (TTM) | 71.31M |
| Operating income (TTM) | -53.93M |
| Net income (TTM) | -77.01M |
| EPS (TTM) | -0.59 |
| EPS (1y forward) | 0.09 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 94.11% |
| Operating margin (TTM) | -71.18% |
| Profit margin (TTM) | -101.64% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 24.21M |
| Net receivables | 22.96M |
| Total current assets | 86.45M |
| Goodwill | 0.00 |
| Intangible assets | 22.70M |
| Property, plant and equipment | 0.00 |
| Total assets | 112.27M |
| Accounts payable | 2.02M |
| Short/Current long term debt | 48.90M |
| Total current liabilities | 68.23M |
| Total liabilities | 137.62M |
| Shareholder's equity | -25.35M |
| Net tangible assets | -25.35M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -82.31M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -82.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -68.59% |
| Return on Invested Capital | -327.05% |
| Cash Return on Invested Capital | -349.56% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| CTIC | S&P500 | |
| Current price drop from All-time high | -100.00% | -9.69% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 29 Sep 2020 | 9 Mar 2009 |
| Avg drop from high | -89.90% | -11.07% |
| Avg time to new high | 169 days | 12 days |
| Max time to new high | 5700 days | 1805 days |
COMPANY DETAILS
Marketcap
1.20B
Marketcap category
Small-cap
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Employees
127
Website
Investor relations
-
SEC filings
CEO
Adam R. Craig
Country
USA
City
Seattle
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner